Insider Buying: Harrow Health, Inc. (NASDAQ:HROW) Major Shareholder Acquires 11,715 Shares of Stock

Harrow Health, Inc. (NASDAQ:HROW) major shareholder Opaleye Management Inc. acquired 11,715 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The stock was purchased at an average price of $10.29 per share, with a total value of $120,547.35. Following the acquisition, the insider now owns 3,786,715 shares of the company’s stock, valued at approximately $38,965,297.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

• On Thursday, April 25th, Opaleye Management Inc. acquired 20,000 shares of Harrow Health stock. The stock was purchased at an average price of $9.97 per share, with a total value of $199,400.00.
• On Friday, April 19th, Opaleye Management Inc. acquired 29,400 shares of Harrow Health stock. The stock was purchased at an average price of $10.56 per share, with a total value of $310,464.00.
• On Thursday, March 28th, Opaleye Management Inc. acquired 50,000 shares of Harrow Health stock. The stock was purchased at an average price of $12.82 per share, with a total value of $641,000.00.
• On Wednesday, March 20th, Opaleye Management Inc. acquired 50,600 shares of Harrow Health stock. The stock was purchased at an average price of $9.65 per share, with a total value of $488,290.00.

Harrow Health Trading Down 2.6 %

NASDAQ HROW opened at $10.00 on Friday. Harrow Health, Inc. has a 12 month low of $7.60 and a 12 month high of $28.25. The stock has a market cap of $353.63 million, a P/E ratio of -13.33 and a beta of 0.48. The stock’s fifty day moving average price is $11.53 and its 200-day moving average price is $11.25. The company has a current ratio of 2.83, a quick ratio of 2.61 and a debt-to-equity ratio of 2.60.

Harrow Health (NASDAQ:HROW) last released its earnings results on Tuesday, March 19th. The company reported ($0.27) EPS for the quarter. Harrow Health had a negative return on equity of 29.48% and a negative net margin of 18.75%. The company had revenue of $36.36 million during the quarter, compared to analysts’ expectations of $37.65 million. As a group, equities analysts forecast that Harrow Health, Inc. will post -0.39 EPS for the current fiscal year.

Institutional Investors Weigh In On Harrow Health

A number of institutional investors have recently modified their holdings of HROW. Allspring Global Investments Holdings LLC purchased a new stake in shares of Harrow Health during the third quarter valued at $26,000. Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in shares of Harrow Health during the third quarter valued at $34,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Harrow Health by 347.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,063 shares of the company’s stock valued at $46,000 after buying an additional 3,155 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Harrow Health by 122.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,073 shares of the company’s stock valued at $90,000 after buying an additional 4,440 shares during the last quarter. Finally, Drive Wealth Management LLC purchased a new stake in shares of Harrow Health during the first quarter valued at $240,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on HROW shares. B. Riley decreased their price objective on Harrow Health from $30.00 to $26.00 and set a “buy” rating for the company in a report on Friday, March 22nd. Craig Hallum began coverage on Harrow Health in a report on Thursday, April 11th. They issued a “buy” rating and a $24.00 price objective for the company.

About Harrow Health

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.